Skip to Main Content

Paper Details

MEN1 mutations mediate clinical resistance to menin inhibition.
Nature
34
2023
Acute leukaemias, KMT2Ar, MEN1, MEN1 gene, MEN1 mutations, MLL1, NPM1, chromatin, human, inhibitor, leukaemia, leukaemogenic, menin, mixed lineage leukaemia 1 gene, nucleophosmin gene, patients, revumenib, xenograft models
Author NameAffiliation
Charlie HattonDana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School
Richard M StoneDana-Farber Cancer Institute
John G DoenchBroad Institute
Gerard M McGeehanSyndax Pharmaceuticals
Scott A ArmstrongDana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School
Scott A ArmstrongDana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School
  • 1 - 6

Datasets

Release 1.2